Hong Kong-listed biotech Ascentage Pharma prices US IPO at $17.25
Ascentage Pharma Group International, a commercial-stage Chinese biotech developing small molecule inhibitors for cancer, raised $126 million by offering 7.3 million ADSs at $17.25, below the as-converted last close of its shares on the Hong Kong Exchange...read more